PCOS Miscarriage Risk by Week and Recurrent Loss Workup

You have had two or three losses. You have PCOS, or you suspect you do, and somewhere on the internet you read that PCOS triples your miscarriage risk and that someone has told you to take metformin, steroids, or progesterone, or all three at once. Before any of that, I am sorry. Recurrent loss is one of the hardest places to be, and the PCOS overlay does not make the question simpler. This post tells you what the evidence actually says, and what an honest workup focuses on.

I want to name what I see in clinic with PCOS and recurrent miscarriage. Patients arrive carrying a folder of conflicting advice and one persistent fear: that PCOS is the reason, and that they should have done something differently. The 2023 international PCOS guideline, led by Teede and the Centre for Research Excellence in PCOS, opens with the position that PCOS is a heterogeneous condition with multiple phenotypes, and that pregnancy outcomes are influenced by features (insulin resistance, hyperandrogenism, obesity, anovulation) that vary widely between individuals.⁸ You and another person with PCOS are not running the same cycle, and the recurrent loss conversation needs to start there.

The recurrent pregnancy loss (RPL) threshold has shifted. ESHRE 2022 defines it as two or more pregnancy losses, consecutive or not.¹ ASRM uses two or more clinical pregnancy losses.² Some older definitions said three; the literature has moved because two losses warrant a workup. You are not jumping the queue by asking.

What the evidence actually says about PCOS and miscarriage risk

The honest summary: pooled estimates suggest people with PCOS have approximately 1.4 to 3-fold higher risk of early miscarriage compared with the general population, with a wide range across studies that reflects the heterogeneity of the syndrome.³,⁴ The Boomsma 2006 meta-analysis in Human Reproduction Update was foundational, reporting an odds ratio for miscarriage of about 3 in unselected PCOS pregnancies, but more recent cohorts adjusting for BMI and metabolic status show smaller effects.³ Palomba's 2015 review documents the same pattern: PCOS is associated with miscarriage, the effect is modest in well-matched cohorts, and much of the excess risk tracks with insulin resistance and obesity rather than PCOS itself.⁴

The searches asking about PCOS miscarriage risk by week deserve a direct answer. Most PCOS-associated losses are first-trimester, before 13 weeks, and most are still chromosomal in origin. PCOS does not change the dominance of chromosomal causes; it adds modestly to risk on top. The "by week" framing implies a granular weekly risk curve that the literature does not really support. What we can say: PCOS does not meaningfully elevate second- and third-trimester loss in the way it modestly elevates first-trimester loss, and the highest-risk window is the same as the general population, roughly weeks 5 through 10.

A classic narrative claimed PCOS causes miscarriage through elevated luteinising hormone (LH). That story has not held up. LH suppression with GnRH agonists in PCOS does not reduce miscarriage risk in trials.⁵ ESHRE 2022 explicitly states that PCOS is not classified as a cause of recurrent pregnancy loss but is a relevant condition to assess and optimise as part of the workup.¹ That nuance is important. PCOS is on the list. PCOS is not the whole list.

The mechanisms that might matter

Several biological pathways have been linked to PCOS and early loss. I list them so that when your RE or OB raises one of them, you know what is being discussed.

Insulin resistance and hyperinsulinaemia: higher circulating insulin is associated with altered endometrial gene expression, impaired decidualisation (the structural and biochemical preparation of the endometrium for implantation), and elevated plasminogen activator inhibitor-1 (PAI-1), a marker of impaired fibrinolysis. Insulin-driven hyperandrogenaemia may also affect the endometrium directly. This is the mechanism with the strongest mechanistic evidence and the clearest target for intervention.

Hyperandrogenaemia: elevated testosterone and free androgen index have been associated with miscarriage risk in some cohorts, though evidence is mixed.⁵ The Cocksedge 2008 study examined free androgen index as a predictor of subsequent pregnancy outcome in recurrent miscarriage and found a relationship, but later cohorts have been less consistent.

Obesity, where it coexists: independent of PCOS, BMI above 30 raises miscarriage risk and adverse pregnancy outcomes. In PCOS phenotypes with obesity, the effects are partially separable; the metabolic features carry the risk more than the diagnosis itself.

Endometrial environment: PCOS endometrium shows progesterone resistance and altered gene expression in some studies. Whether this drives losses or is a marker of the underlying metabolic state is debated.

Thyroid and prolactin: both abnormalities are more common in PCOS, and both, when uncorrected, increase loss risk. Easy to check, often missed.

The practical takeaway from the mechanism literature is this: in PCOS-related recurrent loss, the workup pays attention to the metabolic features and the endometrial preparation, not to LH suppression or empirical immunological treatments.

What an RPL workup looks like when PCOS is part of the picture

The core couple workup, per ESHRE 2022 and ASRM, is the same regardless of whether one partner has PCOS.¹,²

Core workup: structural uterine assessment by transvaginal ultrasound, saline-infusion sonohysterography, or hysteroscopy; antiphospholipid antibody screen (lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2-glycoprotein I) with a 12-week repeat for confirmation; thyroid function and thyroid peroxidase antibodies; prolactin; parental karyotype in selected cases; products of conception cytogenetics where surgical management of a loss is performed.

PCOS-specific additions worth requesting:

• Fasting insulin and a 2-hour oral glucose tolerance test with insulin levels, to characterise insulin resistance directly.
• Vitamin D, particularly if not recently checked. Deficiency is common in PCOS.
• HbA1c to characterise glycaemic exposure over the preceding three months.
• Free testosterone and SHBG if not recently measured, particularly if the hyperandrogenic phenotype is present.
• Repeat AMH if IVF is being planned or reconsidered.

What I would not pay out of pocket for in this setting: routine inherited thrombophilia panels (Factor V Leiden, prothrombin G20210A, MTHFR, protein C/S deficiency), natural killer cell testing (peripheral or uterine), HLA typing, Th1/Th2 cytokine panels, or endometrial receptivity assays. ESHRE 2022 explicitly advises against routine use of all of these outside research settings.¹ Private clinics market them frequently; the evidence does not support them. This is the area where recurrent loss patients with PCOS get exploited financially.

Treatments with evidence, and treatments without

The most common question after a PCOS recurrent loss workup is what to take in the next pregnancy. Here is what the evidence actually shows.

Metformin: evidence on miscarriage reduction in PCOS is mixed. Early studies suggested benefit; larger and more recent trials including Cochrane reviews show limited or no clear effect on live birth in unselected PCOS pregnancies.⁷ Metformin remains reasonable in the insulin-resistant phenotype for metabolic reasons and may be continued into pregnancy under obstetric supervision in some cases. It is not a universal recommendation for everyone with PCOS planning a next pregnancy after recurrent loss.

Levothyroxine: indicated when TSH is elevated, particularly with TPO antibody positivity. Good evidence in subclinical hypothyroidism plus antibodies. Optimise the dose before conception.

Low-dose aspirin: not first-line for unexplained recurrent loss alone. Appropriate when PCOS coexists with other preeclampsia risk factors and the next pregnancy carries that combined risk profile.

Vaginal progesterone in early pregnancy: the PRISM trial showed that vaginal micronised progesterone 400 mg twice daily from a positive test through 16 weeks improves live birth in women with prior miscarriage and current early-pregnancy bleeding, with the strongest effect in those with three or more prior losses.⁶ This is the relevant evidence base. It is not a blanket recommendation for all PCOS, and the dose matters: 400 mg vaginally, twice daily.

Treatments I am cautious about: empirical corticosteroids, intralipid infusions, IVIG, and anticoagulation without a specific indication. Most lack good RCT evidence in this context, and several have meaningful side-effect profiles. If they are being recommended to you on the basis of NK cell testing or immune profiling, the underlying tests themselves are not supported.

What changes for the next pregnancy

The point of a PCOS-aware recurrent loss workup is the plan for the next attempt. Here is the shape of that plan.

Preconception optimisation: HbA1c into the normal range, ideally below 6.0 percent before conception. Weight optimisation if BMI is contributing, with realistic targets (a 5 to 10 percent reduction can shift insulin sensitivity meaningfully). Vitamin D repletion to a serum level of at least 30 ng/mL. Thyroid optimised with TSH ideally below 2.5 mIU/L. Folate at 400 to 800 mcg daily, started at least one month before conception.

Early pregnancy plan: serial beta-hCG to confirm appropriate doubling. Early ultrasound at 6.5 to 7 weeks for viability. Reassurance scans more frequently in the first trimester if anxiety is high; the "tender loving care" model has observational support in recurrent loss. Low threshold to start vaginal progesterone if early bleeding occurs.

Insulin-resistant phenotype specifically: continue metformin into pregnancy under obstetric supervision if you and your OB agree the metabolic indication justifies it. Weigh the evidence honestly with your team rather than assuming benefit.

Mental health support: not optional. Recurrent loss has documented increased rates of depression, anxiety, and post-traumatic stress symptoms, and the next pregnancy is psychologically harder than the first. The companion post TTC grief and when to see a therapist walks the actual referral routes.

What's normal, what's a red flag

Normal in this setting is a workup that finds no single cause, even when done thoroughly. Up to half of recurrent loss workups come back without a clear answer. That is hard. It is also not a failure of the workup.

Red flags worth pursuing further include aneuploid POC results in three consecutive losses (which suggests parental karyotyping), recurrent late-first-trimester or early second-trimester losses (which suggests detailed cavity assessment), and a personal or strong family thrombosis history (which justifies a specialist-led thrombophilia workup, separate from a routine panel).

What to ask before your next appointment

Bring this list.

• "Are we using ESHRE 2022 or ASRM criteria for my workup? What is included?"
• "Has my PCOS phenotype been characterised? Is the insulin resistance treated?"
• "If we find nothing on workup, what is your specific plan for the next pregnancy? Early scans, progesterone with bleeding, thyroid target?"
• "What is your evidence for any empirical treatment you are recommending?"
• "Can you connect me with a fertility-aware therapist as part of the workup?"

What you can do this week

1. Request your most recent HbA1c, TSH, and vitamin D if you do not have them. These three numbers shape the conversation.
2. If you are between losses and the next pregnancy is months away, start folate at 400 to 800 mcg daily now. This is preconception care, not premature optimism.
3. Book a fertility-aware mental health consultation in parallel to the medical workup. The workup will take 8 to 12 weeks. The grief is happening now.

The honest summary on PCOS miscarriage risk by week: most of the excess risk sits in the first trimester, most of that risk tracks with insulin and BMI, and a calm evidence-based workup is what tilts the next pregnancy in your favour.

What's next

• For the full overview of recurrent loss including the progesterone evidence: recurrent pregnancy loss, when to ask for a workup
• For the test-by-test breakdown: the recurrent loss workup, tests worth asking for
• For the mental health side: TTC grief and when to see a therapist
• For the relational strain: when your marriage bends under TTC
• If a different path is on the table: changing direction, from IVF to donor, adoption, or childfree

Sources

1. ESHRE Guideline Group on RPL. ESHRE guideline: recurrent pregnancy loss: an update in 2022. Human Reproduction Open 2023;2023(1):hoad002. https://doi.org/10.1093/hropen/hoad002
2. Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertility and Sterility 2012;98(5):1103-1111. https://doi.org/10.1016/j.fertnstert.2012.06.048
3. Boomsma CM, Eijkemans MJC, Hughes EG, Visser GHA, Fauser BCJM, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Human Reproduction Update 2006;12(6):673-683. https://doi.org/10.1093/humupd/dml036
4. Palomba S, de Wilde MA, Falbo A, Koster MPH, La Sala GB, Fauser BCJM. Pregnancy complications in women with polycystic ovary syndrome. Human Reproduction Update 2015;21(5):575-592. https://doi.org/10.1093/humupd/dmv029
5. Cocksedge KA, Saravelos SH, Wang Q, Tuckerman E, Laird SM, Li TC. Does free androgen index predict subsequent pregnancy outcome in women with recurrent miscarriage? Human Reproduction 2008;23(4):797-802. https://doi.org/10.1093/humrep/den022
6. Coomarasamy A, Devall AJ, Cheed V, et al. A randomized trial of progesterone in women with bleeding in early pregnancy (PRISM). New England Journal of Medicine 2019;380(19):1815-1824. https://doi.org/10.1056/NEJMoa1813730
7. Tso LO, Costello MF, Albuquerque LET, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2020;(12):CD006105. https://doi.org/10.1002/14651858.CD006105.pub4
8. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility 2023;120(4):767-793. https://doi.org/10.1016/j.fertnstert.2023.07.025